Entospletinib

Drug Profile

Entospletinib

Alternative Names: ENTO; GS-9973

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CGI Pharmaceuticals
  • Developer CGI Pharmaceuticals; Gilead Sciences; Lymphoma Academic Research Organisation
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Imidazoles; Indazoles; Morpholines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I Acute lymphoblastic leukaemia; Cancer
  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 22 Jun 2017 Gilead Sciences completes a phase Ib/II trial for Non-Hodgkin lymphoma (Combination therapy; Second-line therapy or greater) in USA, France, Hungary and Spain(PO) (NCT02568683) (EudraCT2015-002731-17)
  • 02 Jun 2017 Efficacy and adverse events data from a phase II trial in Haematological malignancies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 May 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in Japan (PO) (NCT03135028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top